Bristol Myers Squibb Advances Targeted Protein Degradation Platform with New Clinical Data at EHA 2025
Key Insights
Bristol Myers Squibb (search) presented updated clinical findings on investigational CELMoD agents mezigdomide and iberdomide for multiple myeloma (search), and golcadomide for non-Hodgkin lymphoma (search) at the 2025 European Hematology Association Annual Congress.
The company revealed first results for its first-in-class oral BCL6 ligand-directed degrader (BMS-986458) in non-Hodgkin lymphoma (search), expanding its targeted protein degradation portfolio.
These protein degraders are designed to target and degrade disease-driving proteins that are difficult to address with conventional small-molecule inhibitors, potentially enhancing existing therapies and overcoming resistance.
Bristol Myers Squibb (search) announced new clinical data from its targeted protein degradation platform at the 2025 European Hematology Association (EHA) Annual Congress, held June 12-15 in Milan, Italy. The presentations featured updated clinical findings on the company's investigational oral CELMoD agents mezigdomide and iberdomide in multiple myeloma (search), golcadomide in non-Hodgkin lymphoma (search), and first results for its first-in-class oral BCL6 ligand-directed degrader (BMS-986458) in non-Hodgkin lymphoma.
Expanding Targeted Protein Degradation Portfolio
The latest data for the three lead CELMoD agents and BCL6 LDD underscore the potential impact these therapies may have in addressing significant unmet medical needs in hematologic malignancies (search). These agents represent part of Bristol Myers Squibb (search)'s continuing research across targeted protein degradation, which encompasses additional CELMoD agents, LDDs and degrader antibody conjugates (DACs) across blood cancers (search) and solid tumours (search), as well as non-malignant hematologic disorders.
Protein degraders, including CELMoD agents and LDDs, are therapies designed to target and degrade specific proteins that drive diseases, including many proteins that are difficult to target through conventional small-molecule inhibitors. These innovative agents have the possibility to enhance the efficacy of existing therapies and overcome resistance in various malignancies, potentially improving patient outcomes.
Clinical Development Progress
"As a leader in the field of targeted protein degradation, we are committed to applying our decades of expertise to the development of these next wave of agents," said Anne Kerber, senior vice president, head of development, haematology, oncology and cell therapy for Bristol Myers Squibb (search). "The efficacy and safety data presented at the EHA Annual Meeting this year is promising and reinforces the potential of CELMoD agents in combination with other standard treatments."
Kerber noted that these analyses add to the body of evidence for these programmes as the company continues pivotal studies for each of the agents, with readouts anticipated in the next year and onwards.
Strategic Focus on Cancer Care
Bristol Myers Squibb (search)'s cancer research goal is to deliver medicines that offer each patient a better, healthier life and to make cure a possibility. Building on a legacy across a broad range of cancers that have changed survival expectations for many, Bristol Myers Squibb researchers are exploring new frontiers in personalized medicine and, through innovative digital platforms, are turning data into insights that sharpen their focus.
The company's deep understanding of causal human biology, cutting-edge capabilities and differentiated research platforms uniquely position it to approach cancer from every angle. As a leader in cancer care, Bristol Myers Squibb (search) is working to empower all people with cancer to have a better future, addressing all aspects of care from diagnosis to survivorship.